Document ID: chunk:federal_register_of_legislation:F2025C00158:schedule:5
Version: federal_register_of_legislation:F2025C00158
Segment Type: schedule
Provision Reference: sch 5
Character Range: 18621223–18622997

Schedule 5
Schedule 5................  am F2024L00498
                            ed C1
                            am F2024L00603 (Sch 1 items 406, 407, 427, 431 (excluding the entry for Quetiapine in the form Tablet (modified release) 150 mg (as fumarate)) md not incorp); F2024L00825 (Sch 1 item 392 md not incorp)
                            ed C3
                            am F2024L00943; F2024L01104
                            ed C5
                            am F2024L01237; F2024L01389 (Sch 1 items 445, 446 md not incorp); F2024L01524; F2024L01730; F2025L00062

Endnote 5—Editorial changes
In preparing this compilation for registration, the following kinds of editorial change(s) were made under the Legislation Act 2003.

Schedule 1, Part 1, entries for Levothyroxine in the form Tablet containing 50 micrograms anhydrous levothyroxine sodium

Kind of editorial change

Give effect to the misdescribed amendments as intended

Details of editorial change

Schedule 1 item 110 of the National Health (Listing of Pharmaceutical Benefits) Amendment (February Update) Instrument 2025 (PB 1 of 2025) provides as follows:

[110] Schedule 1, Part 1, entry for Levothyroxine in the form Tablet containing 50 micrograms anhydrous levothyroxine sodium
(a) omit from the column headed "Authorised Prescriber" (all instances): MP NP substitute (all instances): MP NP MW
(b) insert in the column headed "Circumstances" (all instances): C16261

However, multiple entries of this form or brand of drug exist.

This compilation was editorially changed to apply the amendments to the entries for Levothyroxine in the form Tablet containing 50 micrograms anhydrous levothyroxine sodium in Part 1 of Schedule 1 to give effect to the misdescribed amendments as intended.